The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Effects of Valsartan on Circulating Brain Natriuretic Peptide and Norepinephrine in Symptomatic Chronic Heart Failure: The Valsartan Heart Failure Trial (Val-HeFT)
Abstract
Background— Brain natriuretic peptide (BNP) and norepinephrine (NE) are strongly related to severity of and are independent predictors of outcome in heart failure. The long-term effects of angiotensin receptor blockers on BNP and NE in heart failure patients are not known. Methods and Results— Both BNP and NE were measured in 4284 patients randomized to valsartan or placebo in the Valsartan Heart Failure Trial (Val-HeFT) at baseline and 4, 12, and 24 months after randomization. The effects of valsartan were tested by ANCOVA, controlling for baseline values and concomitant ACE inhibitors and/or β-blockers. BNP and NE concentrations were similar at baseline in the 2 groups and were decreased by valsartan starting at 4 months and up to 24 months. BNP increased over time in the placebo group. At the end point, least-squares mean (±SEM) BNP increased from baseline by 23±5 pg/mL in the placebo group (n=1979) but decreased by 21±5 pg/mL (n=1940) in the valsartan group ( P <0.0001). NE increased by 41±6 pg/mL (n=1979) and 12±6 pg/mL (n=1941) for placebo and valsartan, respectively ( P =0.0003). Concomitant therapy with both ACE inhibitors and β-blockers significantly reduced the effect of valsartan on BNP but not on NE ( P for interaction=0.0223 and 0.2289, respectively). Conclusions— In Val-HeFT, the largest neurohormone study in patients with symptomatic chronic heart failure, BNP and NE rose over time in the placebo group. Valsartan caused sustained reduction in BNP and attenuated the increase in NE over the course of the study. These neurohormone effects of valsartan are consistent with the clinical benefits reported in Val-HeFT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
Self-citationEpstein, F. H., Levin, E. R., Gardner, D. G., & Samson, W. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807303390507 · Cited by 1,927
Francis, G. S., Benedict, C., Johnstone, D. E., Kirlin, P. C., Nicklas, J., Liang, C. S., Kubo, S. H., Rudin-Toretsky, E., & Yusuf, S. (1990) · Circulation · doi:10.1161/01.cir.82.5.1724 · Cited by 1,388
Swedberg, K., Eneroth, P., Kjekshus, J., & Wilhelmsen, L. (1990) · Circulation · doi:10.1161/01.cir.82.5.1730 · Cited by 1,153
A Trial of the Beta-Blocker Bucindolol in Patients with Advanced Chronic Heart Failure
(2001) · New England Journal of Medicine · doi:10.1056/nejm200105313442202 · Cited by 1,007
McKelvie, R. S., Yusuf, S., Pericak, D., Avezum, A., Burns, R. J., Probstfield, J., Tsuyuki, R. T., White, M., Rouleau, J., Latini, R., et al. (1999) · Circulation · doi:10.1161/01.cir.100.10.1056 · Cited by 692
Self-citationCohn, J. N., Johnson, G. R., Shabetai, R. W., Loeb, H. S., Tristani, F. E., Rector, T. S., Smith, R., & Fletcher, R. D. (1993) · PubMed · Cited by 533
Self-citationGoldstein, D. S., Feuerstein, G., Izzo, J. L., Kopin, I. J., & Keiser, H. R. (1981) · Life Sciences · doi:10.1016/0024-3205(81)90139-9 · Cited by 467
Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure
Koglin, J., Pehlivanli, S., Schwaiblmair, M., Vogeser, M., Cremer, P., & vonScheidt, W. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01672-2 · Cited by 404
Cohn, J. N., Ziesche, S., Smith, R., Anand, I., Dunkman, W. B., Loeb, H., Cintron, G., Boden, W., Baruch, L., Rochin, P., et al. (1997) · Circulation · doi:10.1161/01.cir.96.3.856 · Cited by 358
Self-citation
Cited by
B-type natriuretic peptide in cardiovascular disease
de Lemos, J. A., McGuire, D. K., & Drazner, M. H. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13976-1 · Cited by 1,067
Anand, I. S., Fisher, L. D., Chiang, Y.-T., Latini, R., Masson, S., Maggioni, A. P., Glazer, R. D., Tognoni, G., & Cohn, J. N. (2003) · Circulation · doi:10.1161/01.cir.0000054164.99881.00 · Cited by 864
Self-citationBettencourt, P., Azevedo, A., Pimenta, J., Friões, F., Ferreira, S., & Ferreira, A. (2004) · Circulation · doi:10.1161/01.cir.0000144310.04433.be · Cited by 729
Plasma Brain Natriuretic Peptide-Guided Therapy to Improve Outcome in Heart Failure
Jourdain, P., Jondeau, G., Funck, F., Gueffet, P., Le Helloco, A., Donal, E., Aupetit, J. F., Aumont, M. C., Galinier, M., Eicher, J. C., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.10.081 · Cited by 646
Filippatos, G., Anker, S. D., Böhm, M., Gheorghiade, M., Køber, L., Krum, H., Maggioni, A. P., Ponikowski, P., Voors, A. A., Zannad, F., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw132 · Cited by 446
Self-citation
Metadata
- Authors
- Latini, R., Masson, S., Anand, I., Judd, D., Maggioni, A. P., Chiang, Y.-T., Bevilacqua, M., Salio, M., Cardano, P., Dunselman, P. H. J. M., Holwerda, N. J., Tognoni, G., & Cohn, J. N.
- Venue
- Circulation
- Published
- 2002-11-05
- Volume
- 106
- Issue
- 19
- Pages
- 2454-2458
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2141716584
- Cited by
- 291
- References
- 20
- FWCI
- 16.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of Valsartan on Circulating Brain Natriuretic Peptide and Norepinephrine in Symptomatic Chronic Heart Failure: The Valsartan Heart Failure Trial (Val-HeFT). https://app.cochat.ai/papers/10.1161/01.cir.0000036747.68104.ac
- The paper
- Latini, R., Masson, S., Anand, I., Judd, D., Maggioni, A. P., Chiang, Y.-T., Bevilacqua, M., Salio, M., Cardano, P., Dunselman, P. H. J. M., Holwerda, N. J., Tognoni, G., & Cohn, J. N. (2002). Effects of Valsartan on Circulating Brain Natriuretic Peptide and Norepinephrine in Symptomatic Chronic Heart Failure: The Valsartan Heart Failure Trial (Val-HeFT). Circulation. https://doi.org/10.1161/01.cir.0000036747.68104.ac
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.